课题基金 / 基金详情

项目摘要

项目成果

Matthew Hall的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The NCATS Early Translation Branch (ETB) hosts a broad and comprehensive program for the discovery of drug candidates directed towards rare diseases and pharmacological tools to probe the function of the human genome. ETB conducts research to understand the underlying principles driving the translation of basic research discoveries into tangible improvements in human health. During this period, the project team worked to validate previously identified inhibitors and activators of WIP1. The team confirmed activity of these molecules in a RapidFire mass spectrometry screening assay, fluorescence reporter orthogonal assay, and binding studies by surface plasmon resonance (SPR). These new scaffolds could be candidates for optimization, which may provide better pharmacokinetics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BRD4 Inhibitors as Potential Therapeutics for Oncology
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2
qHTS to Identify Activators and Inhibitors of Wip1
qHTS to Identify Inducers of Oligodendrocyte-precursor cell (OPC) Remyelination
海外基金